Adaptin Bio

Executive Summary

Adaptin Bio is a preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing a novel drug delivery platform called BRiTE (Brain Bispecific T cell Engager). The platform combines bispecific T cell engagers with specially manipulated polyclonal T cells to enable targeted delivery across the blood-brain barrier. Founded in 2021, the company focuses on addressing central nervous system disorders by leveraging T cell-mediated therapies. As a privately held company with limited public information, its progress and financial status are not disclosed. The technology promises to overcome a key challenge in CNS drug development: crossing the blood-brain barrier. Adaptin Bio's approach is innovative, but it remains in early preclinical stages with no disclosed partnerships, funding rounds, or regulatory filings. The company's success hinges on demonstrating platform feasibility and safety in animal models, followed by progression toward human trials.

Upcoming Catalysts (preview)

• Q4 2025Preclinical Proof-of-Concept Data Publication or Presentation40% success
• Q2 2026First Institutional Funding or Strategic Partnership Announcement30% success
• Q4 2026IND-Enabling Studies Initiation20% success